Jian-Hong Zhong

List of Publications by Year
in descending order

157	4,087	159585 30	155660 55
papers	citations	h-index	g-index

158	158	158	4485
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma. Annals of Surgery, 2014, 260, 329-340.	4.2	382
2	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. Journal of Hepatology, 2018, 69, 1284-1293.	3.7	360
3	Albuminâ€“bilirubin versus Childâ€“Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. British Journal of Surgery, 2016, 103, 725-734.	0.3	242
4	Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma. Cancer Research, 2018, 78, 4731-4744.	0.9	204
5	Comparison of Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma after Liver Resection or Transarterial Chemoembolization. PLoS ONE, 2013, 8, e68193.	2.5	133
6	Hepatic Resection as a Safe and Effective Treatment for Hepatocellular Carcinoma Involving a Single Large Tumor, Multiple Tumors, or Macrovascular Invasion. Medicine (United States), 2015, 94, e396.	1.0	110
7	Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A metaâ€analysis. Hepatology Research, 2010, 40, 943-953.	3.4	94
8	Systematic review comparing the safety and efficacy of conventional and drugâ€eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatology Research, 2015, 45, 190-200.	3.4	73
9	Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials. European Journal of Surgical Oncology, 2012, 38, 286-295.	1.0	71
10	Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget, 2017, 8, 33911-33921.	1.8	62
11	Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. Oncotarget, 2017, 8, 18296-18302.	1.8	54
12	Postoperative therapy options for hepatocellular carcinoma. Scandinavian Journal of Gastroenterology, 2014, 49, 649-661.	1.5	53
13	Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion. American Journal of Surgery, 2019, 217, 739-744.	1.8	53
14	Efficacy of triclosan-coated sutures for reducing risk of surgical site infection in adults: a meta-analysis of randomized clinical trials. Journal of Surgical Research, 2016, 201, 105-117.	1.6	51
15	Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombusï¼ša multicenter study. European Journal of Surgical Oncology, 2019, 45, 1460-1467.	1.0	49
16	Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension: TableÂ1. Gut, 2015, 64, 520.2-521.	12.1	48
17	Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biology and Medicine, 2013, 10, 158-64.	3.0	48
18	Epidermal Growth Factor Gene Polymorphism and Risk of Hepatocellular Carcinoma: A Meta-Analysis. PLoS ONE, 2012, 7, e32159.	2.5	47

#	Article	IF	Citations
19	Prognostic value of PD -L1 expression in patients with primary solid tumors. Oncotarget, 2018, 9, 5058-5072.	1.8	47
20	Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: Propensity score analysis. World Journal of Gastroenterology, 2015, 21, 4627-4634.	3.3	47
21	Hepatic Resection Is Safe and Effective for Patients with Hepatocellular Carcinoma and Portal Hypertension. PLoS ONE, 2014, 9, e108755.	2.5	46
22	Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma. Annals of Surgery, 2021, 274, e1209-e1217.	4.2	45
23	Comparison of Survival of Patients with BCLC Stage A Hepatocellular Carcinoma After Hepatic Resection or Transarterial Chemoembolization: A Propensity Score-Based Analysis. Annals of Surgical Oncology, 2014, 21, 3069-3076.	1.5	44
24	The lncRNA SNHG16 affects prognosis in hepatocellular carcinoma by regulating p62 expression. Journal of Cellular Physiology, 2020, 235, 1090-1102.	4.1	44
25	Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure. Cancer Medicine, 2017, 6, 2357-2369.	2.8	42
26	Microwave ablation versus laparoscopic resection as firstâ€line therapy for solitary 3â€“5â€cm HCC. Hepatology, 2022, 76, 66-77.	7.3	40
27	Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular Carcinoma. Medicine (United States), 2016, 95, e2722.	1.0	38
28	Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. International Journal of Clinical Practice, 2012, 66, 21-27.	1.7	36
29	Improving patient selection for selective internal radiation therapy of intraâ€hepatic cholangiocarcinoma: A metaâ€regression study. Liver International, 2017, 37, 1056-1064.	3.9	35
30	Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. Hpb, 2018, 20, 110-119.	0.3	35
31	Comparison of Long-Term Survival of Patients with Solitary Large Hepatocellular Carcinoma of BCLC Stage A after Liver Resection or Transarterial Chemoembolization: A Propensity Score Analysis. PLoS ONE, 2014, 9, e115834.	2.5	32
32	Efficacy of hepatic resectionvstransarterial chemoembolization for solitary huge hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 9630.	3.3	32
33	A New Theranostic System Based on Endoglin Aptamer Conjugated Fluorescent Silica Nanoparticles. Theranostics, 2017, 7, 4862-4876.	10.0	30
34	Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Journal of Viral Hepatitis, 2018, 25, 1026-1037.	2.0	30
35	Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: A multicenter propensity score matching analysis. Surgery, 2021, 169, 911-920.	1.9	29
36	Impact of Diabetes Mellitus on the Prognosis of Patients with Hepatocellular Carcinoma after Curative Hepatectomy. PLoS ONE, 2014, 9, e113858.	2.5	28

#	Article	IF	Citations
37	Postoperative Use of the Chemopreventive Vitamin K2 Analog in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e58082.	2.5	27
38	Hepatectomy for liver metastases from gastric cancer: a systematic review. BMC Surgery, 2017, 17, 14.	1.3	27
39	Historical Comparison of Overall Survival after Hepatic Resection for Patients With Large and/or Multinodular Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e1426.	1.0	26
40	Systematic review of treatment strategy for recurrent hepatocellular carcinoma. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	26
41	Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. Cancer Immunology, Immunotherapy, 2022, 71, 1063-1074.	4.2	26
42	Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumor Biology, 2014, 35, 8451-8459.	1.8	25
43	Methylenetetrahydrofolate Reductase Gene Polymorphism and Risk of Type 2 Diabetes Mellitus. PLoS ONE, 2013, 8, e74521.	2.5	24
44	New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Journal of Clinical and Translational Hepatology, 2017, 5, 169-176.	1.4	24
45	High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma. Scientific Reports, 2017, 7, 42199.	3.3	23
46	Meta-Analysis of Microsomal Epoxide Hydrolase Gene Polymorphism and Risk of Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e57064.	2.5	23
47	Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. Annals of Surgical Oncology, 2022, 29, 4291-4303.	1.5	23
48	Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. Tumor Biology, 2014, 35, 9459-9468.	1.8	22
49	Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. Tumor Biology, 2014, 35, 12779-12784.	1.8	22
50	Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma. Tumor Biology, 2016, 37, 2435-2441.	1.8	22
51	Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. Clinical and Translational Oncology, 2017, 19, 891-897.	2.4	22
52	A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7Âcm and multiple tumours beyond upâ€toâ€seven criteria. Alimentary Pharmacology and Therapeutics, 2019, 49, 202-210.	3.7	22
53	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Frontiers in Oncology, 2021, 11, 737497.	2.8	22
54	Intermediate-stage HCCâ€"upfront resection can be feasible. Nature Reviews Clinical Oncology, 2015, 12, 295-295.	27.6	21

#	Article	IF	Citations
55	Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis . Cancer Management and Research, 2019, Volume 11, 6011-6018.	1.9	21
56	Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy. Journal of Clinical and Translational Hepatology, 2022, 10, 147-158.	1.4	21
57	Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: retrospective multicentre study. British Journal of Surgery, 2021, 109, 71-78.	0.3	21
58	Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5541-5547.	1.2	21
59	Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World Journal of Hepatology, 2016, 8, 957.	2.0	20
60	Comparison of threeâ€dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus. Cancer Medicine, 2018, 7, 4387-4395.	2.8	20
61	Correlation between serum prealbumin and prognosis of patients with hepatocellular carcinoma after hepatectomy. Journal of Surgical Oncology, 2019, 119, 794-800.	1.7	20
62	Hepatic resection for elderly patients with hepatocellular carcinoma: a systematic review of more than 17,000 patients. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1059-1068.	3.0	19
63	Zoledronate for Metastatic Bone Disease and Pain: A Meta-Analysis of Randomized Clinical Trials. Pain Medicine, 2013, 14, 257-264.	1.9	18
64	Randomized Clinical Trial Comparing Efficacy of Simo Decoction and Acupuncture or Chewing Gum Alone on Postoperative Ileus in Patients With Hepatocellular Carcinoma After Hepatectomy. Medicine (United States), 2015, 94, e1968.	1.0	18
65	Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumor Biology, 2014, 35, 8355-8358.	1.8	17
66	Evaluation of liver regeneration and post-hepatectomy liver failure after hemihepatectomy in patients with hepatocellular carcinoma. Bioscience Reports, 2019, 39, .	2.4	17
67	Association between age and overall survival of patients with hepatocellular carcinoma after hepatic resection. Journal of Surgical Oncology, 2016, 114, 966-970.	1.7	16
68	Controversies and evidence of hepatic resection for hepatocellular carcinoma. BBA Clinical, 2016, 6, 125-130.	4.1	16
69	Outcomes of anatomical versus non-anatomical resection for hepatocellular carcinoma according to circulating tumour-cell status. Annals of Medicine, 2020, 52, 21-31.	3.8	16
70	Single Nucleotide Polymorphism 8q24 rs13281615 and Risk of Breast Cancer: Meta-Analysis of More than 100,000 Cases. PLoS ONE, 2013, 8, e60108.	2.5	15
71	Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials. BMJ Open, 2015, 5, e007258-e007258.	1.9	15
72	Comparative efficacy of postoperative transarterial chemoembolization with or without antiviral therapy for hepatitis B virus-related hepatocellular carcinoma. Tumor Biology, 2015, 36, 6277-6284.	1.8	15

#	Article	IF	Citations
73	Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Oncotarget, 2017, 8, 15047-15056.	1.8	15
74	Clinicopathological characteristics and liver stem cell marker expression in hepatocellular carcinoma involving bile duct tumor thrombi. Tumor Biology, 2016, 37, 5879-5884.	1.8	14
75	S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma. Hepatology International, 2021, 15, 114-126.	4.2	14
76	Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 782-794.	2.8	14
77	Portal hypertension should not be a contraindication of hepatic resection to treat hepatocellular carcinoma with compensated cirrhosis. Hepatology, 2015, 62, 977-978.	7.3	13
78	Postoperative hepatitis B virus reactivation and surgeryâ€induced immunosuppression in patients with hepatitis Bâ€related hepatocellular carcinoma. Journal of Surgical Oncology, 2015, 112, 634-642.	1.7	13
79	Preâ€and postâ€operative HBsAg levels may predict recurrence and survival after curative resection in patients with HBVâ€associated hepatocellular carcinoma. Journal of Surgical Oncology, 2017, 116, 140-148.	1.7	13
80	Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis. Gut, 2020, 69, 1900-1902.	12.1	13
81	Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. World Journal of Hepatology, 2014, 6, 652.	2.0	13
82	Comparison of postoperative immune function in patients with thoracic esophageal cancer after video-assisted thoracoscopic surgery or conventional open esophagectomy. International Journal of Surgery, 2016, 30, 155-160.	2.7	12
83	Macrophage polarization-associated lnc-Ma301 interacts with caprin-1 to inhibit hepatocellular carcinoma metastasis through the Akt/Erk1 pathway. Cancer Cell International, 2021, 21, 422.	4.1	12
84	Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma. Journal of Cancer, 2020, 11, 3400-3406.	2.5	11
85	mEH Tyr113His polymorphism and the risk of ovarian cancer development. Journal of Ovarian Research, 2013, 6, 40.	3.0	10
86	Pre-, Peri-, and Postoperative Oral Administration of Branched-Chain Amino Acids for Primary Liver Cancer Patients for Hepatic Resection: A Systematic Review. Nutrition and Cancer, 2014, 66, 517-522.	2.0	10
87	Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL. OncoTargets and Therapy, 2016, Volume 9, 4593-4603.	2.0	10
88	Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. Journal of Hepatology, 2017, 67, 885-886.	3.7	10
89	Optimizing stage of single large hepatocellular carcinoma. Medicine (United States), 2017, 96, e6608.	1.0	10
90	Serum Prealbumin is Negatively Associated with Survival in Hepatocellular Carcinoma Patients after Hepatic Resection. Journal of Cancer, 2019, 10, 3006-3011.	2.5	10

#	Article	IF	Citations
91	Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma. Journal of Cancer, 2020, 11, 6437-6444.	2.5	10
92	Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy. PLoS ONE, 2017, 12, e0174222.	2.5	10
93	The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma. Tumor Biology, 2015, 36, 8271-8272.	1.8	9
94	Association between COX-2 gene polymorphisms and risk of hepatocellular carcinoma development: a meta-analysis. BMJ Open, 2015, 5, e008263.	1.9	9
95	Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 11-13.	3.7	9
96	Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review. Oncotarget, 2017, 8, 18537-18549.	1.8	9
97	Weâ€™re Still in an Update Process of the BCLC System. Annals of Surgery, 2018, 267, e23-e24.	4.2	9
98	Analysis of Clinicopathological Characteristics and Prognosis of Young Patients with Hepatocellular Carcinoma after Hepatectomy. Journal of Clinical and Translational Hepatology, 2020, 8, 1-7.	1.4	9
99	Repeat hepatic resection versus percutaneous ablation for the treatment of recurrent hepatocellular carcinoma: meta-analysis. BJS Open, 2022, 6, .	1.7	9
100	Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges. Journal of Clinical and Translational Hepatology, 2022, 10, 955-964.	1.4	9
101	Association of the miR-196a2 C>T and miR-499 A>G polymorphisms with hepatitis B virus-related hepatocellular carcinoma risk: an updated meta-analysis. OncoTargets and Therapy, 2016, 9, 2111.	2.0	8
102	Should hepatic resection be recommended to patients with hepatocellular carcinoma and portal vein invasion?. Journal of Hepatology, 2016, 65, 1057-1058.	3.7	8
103	Contrast-Enhanced Ultrasound to Monitor Early Recurrence of Primary Hepatocellular Carcinoma after Curative Treatment. BioMed Research International, 2018, 2018, 1-8.	1.9	8
104	Association between polymorphisms in MicroRNA target sites of RAD51D genes and risk of hepatocellular carcinoma. Cancer Medicine, 2019, 8, 2545-2552.	2.8	8
105	Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2020, 14, 749-756.	3.0	8
106	The upward trend in the immunotherapy utilization for hepatobiliary cancers. Hepatobiliary Surgery and Nutrition, 2021, 10, 692-695.	1.5	8
107	Doseâ€“Response Between Serum Prealbumin and All-Cause Mortality After Hepatectomy in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 596691.	2.8	8
108	Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems. Scandinavian Journal of Gastroenterology, 2011, 46, 645-651.	1.5	7

#	Article	IF	Citations
109	Retrobulbar metastasis and intracranial invasion from postoperative hepatocellular carcinoma: A case report and review of the literature. Oncology Letters, 2015, 9, 721-726.	1.8	7
110	Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection. OncoTargets and Therapy, 2016, Volume 9, 6897-6907.	2.0	7
111	Combination of 5-fluorouracil and 2-morphilino-8-phenyl-4H-chromen-4-one may inhibit liver cancer stem cell activity. Tumor Biology, 2016, 37, 10943-10958.	1.8	7
112	Postoperative Antiviral Therapy With Nucleos(t)ide Analogs in Patients With Hepatitis B Virus–Related Hepatocellular Carcinoma. Annals of Surgery, 2017, 265, e46-e47.	4.2	7
113	Is radioembolization or sorafenib the best option for patients with hepatocellular carcinoma and portal vein invasion?. Liver International, 2016, 36, 1715-1715.	3.9	6
114	Subclassification of patients with solitary hepatocellular carcinoma based on post-hepatectomy survival: a large retrospective study. Tumor Biology, 2016, 37, 5327-5335.	1.8	6
115	Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection: A Multicenter Observational Study. Frontiers in Oncology, 2021, 11, 700228.	2.8	6
116	Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget, 2017, 8, 51810-51816.	1.8	6
117	Efficacy of hepatic resection for huge (â‰¥ 10 cm) hepatocellular carcinoma: good prognosis associated with the uninodular subtype. International Journal of Clinical and Experimental Medicine, 2015, 8, 20581-8.	1.3	6
118	Transarterial Embolization With or Without Chemotherapy: What Should Be the Indication for Patients With Hepatocellular Carcinoma?. Journal of Clinical Oncology, 2017, 35, 257-258.	1.6	5
119	Hepatic resection is superior to transarterial chemoembolization for treating intermediateâ€stage hepatocellular carcinoma. Liver International, 2017, 37, 1083-1084.	3.9	5
120	Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. Expert Review of Gastroenterology and Hepatology, 2019, 13, 1077-1088.	3.0	5
121	Letter to the Editor: Hepatic Resection Compared to Chemoembolization in Intermediateâ€•to Advancedâ€Stage Hepatocellular Carcinoma: A Comment For Moving Forward. Hepatology, 2019, 70, 446-447.	7.3	5
122	Development and validation of a nomogram for assessing survival in patients with hepatocellular carcinoma after hepatectomy. Bioscience Reports, 2020, 40, .	2.4	5
123	Properly assessing CD133 as a risk factor for poor prognosis in patients with hepatocellular carcinoma after resection. Tumor Biology, 2015, 36, 4937-4938.	1.8	4
124	Is laparoscopic hepatectomy superior to open hepatectomy for hepatocellular carcinoma?. World Journal of Hepatology, 2017, 9, 167.	2.0	4
125	Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. Frontiers in Oncology, 2021, 11, 783339.	2.8	4
126	Letter: pre- and post-operative anti-viral therapy is important for patients with hepatitis B virus-related hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2015, 41, 789-790.	3.7	3

#	Article	IF	Citations
127	Comment on â€œEvaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysisâ€• Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-2.	1.9	3
128	Therapeutic role of systematic lymphadenectomy in early-stage endometrial cancer: A systematic review. Oncology Letters, 2016, 11, 3849-3857.	1.8	3
129	Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy. Molecular and Clinical Oncology, 2016, 5, 3-6.	1.0	3
130	Comment on tumor size as a prognostic factor for solitary HCC after resection. Journal of Surgical Oncology, 2016, 113, 593-593.	1.7	3
131	Postoperative antiviral therapy with nucleos(t)ide analogs for patients with hepatitis B virus-related hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, e29-e30.	1.5	3
132	Response to Comment on â€œâ€˜Development and Validation of a Nomogram to Preoperatively Estimate Post-Hepatectomy Liver Dysfunction Risk and Long-Term Survival in Patients With Hepatocellular Carcinomaâ€™. Annals of Surgery, 2020, Publish Ahead of Print, e791-e792.	4.2	3
133	Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy. World Journal of Surgical Oncology, 2022, 20, .	1.9	3
134	Does the elevation of serum carbohydrate antigen 19-9 level predict poor overall survival in patients with hepatocellular carcinoma?. Tumor Biology, 2015, 36, 8273-8274.	1.8	2
135	Comment on a meta-analysis comparing hepatic resection or transarterial chemoembolization as initial treatment for hepatocellular carcinoma. Drug Design, Development and Therapy, 2015, 9, 5623.	4.3	2
136	Hepatic Resection Improves Long-Term Survival of Patients with Large and/or Multinodular Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2015, 19, 2288-2289.	1.7	2
137	Adjuvant Immunotherapy for Postoperative Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 1639-1640.	1.3	2
138	Hepatic venous pressure gradient for preoperative assessment of patients with resectable hepatocellular carcinoma: A comment for moving forward. Journal of Hepatology, 2016, 65, 230-231.	3.7	2
139	Letter: clinical outcomes of <scp>HB</scp>sAg loss in chronic <scp>HBV</scp> infection. Alimentary Pharmacology and Therapeutics, 2016, 44, 535-536.	3.7	2
140	Comment on stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma. Journal of Surgical Oncology, 2016, 113, 715-715.	1.7	2
141	Letter: role of tenofovir to prevent motherâ€toâ€child transmission of hepatitis B virus. Alimentary Pharmacology and Therapeutics, 2017, 46, 562-563.	3.7	2
142	Letter: older age and male gender increase the risk of hepatocellular carcinoma after hepatitis B surface antigen (<scp>HB</scp>sAg) seroclearance. Alimentary Pharmacology and Therapeutics, 2017, 46, 906-908.	3.7	2
143	Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients. Bioscience Reports, 2021, 41, .	2.4	2
144	Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after surgery: A comment for moving forward. World Journal of Hepatology, 2016, 8, 605.	2.0	2

#	Article	IF	Citations
145	Letter: sex disparity in prognosis of patients with hepatocellular carcinoma after resection. Alimentary Pharmacology and Therapeutics, 2020, 52, 1767-1768.	3.7	2
146	Comment on: Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. Journal of Surgical Oncology, 2015, 112, 907-908.	1.7	1
147	Possible associations between ascites and vascular invasion in patients with hepatocellular carcinoma. Tumor Biology, 2015, 36, 4933-4934.	1.8	1
148	Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: A multicenter propensity score matching analysis. European Journal of Surgical Oncology, 2022, 48, 1078-1086.	1.0	1
149	Try113His and His139Arg polymorphisms in the microsomal epoxide hydrolase gene are not associated with risk of breast cancer. Tumor Biology, 2014, 35, 8087-8093.	1.8	0
150	Is drugâ€eelutingâ€bead transcatheter arterial chemoembolization (TACE) associated with better tumor response than conventional TACE in a metaâ€eanalysis?: Authorsâ€™ reply. Hepatology Research, 2015, 45, 1260-1261.	3.4	0
151	Are another 5 years of adjuvant aromatase inhibitor therapy needed?. Breast Cancer: Targets and Therapy, 2016, Volume 8, 207-209.	1.8	0
152	Association of blood transfusion during resection for hepatocellular carcinoma with postoperative recurrence and overall survival: A cautionary comment. Journal of Hepatology, 2016, 65, 228.	3.7	0
153	Are We Sure that Blood Transfusion is Associated with Recurrence of Hepatocellular Carcinoma After Hepatectomy?. World Journal of Surgery, 2016, 40, 2291-2292.	1.6	0
154	A premature proposal for new liver cancer seromarkers. Tumor Biology, 2016, 37, 4293-4294.	1.8	0
155	Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinomaâ€"authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 616-617.	3.7	0
156	The role of SSM and LSPS in predicting posthepatectomy liver failure should be further evaluated. Journal of Surgical Oncology, 2019, 119, 402-403.	1.7	0
157	Association of CK19 expression with the efficacy of adjuvant transarterial chemoembolization after hepatic resection in hepatocellular carcinoma patients at high risk of recurrence.. Journal of Clinical and Translational Research, 2022, 8, 71-79.	0.3	0